Kenneth Raymond explains why contributing your CMT symptom data to the Global Registry for Inherited Neuropathies (GRIN) matters for research.

GRIN was created by HNF to solve a core problem in CMT research: the lack of quantitative, structured data on how CMT presents and progresses across a large population. The registry collects private, de-identified data that is valuable to biotech and pharmaceutical researchers working to develop treatments.

A large registry serves researchers in two important ways. First, it helps them gauge whether investigational drugs are having an effect by providing a wide window of real-world symptom data to compare against. Second, it helps establish prevalence rates that are essential for assembling a sufficient patient population for clinical trials.

Ultimately, every person who joins GRIN strengthens the foundation for CMT drug development. Join GRIN today to add your data to this growing resource.